Tier 1 — highest

Geroprotective insights into the natural metabolite spermidine in aging and age-related diseases

Zhirui Jiang, Sen Tong, James L Kirkland, Yu Sun

npj Aging 2026 Online ahead of print (20 Jul 2026)

Bibliography

PubMed: PMID 42477363
DOI: 10.1038/s41514-026-00448-9
Funding: Supported by National Natural Science Foundation of China grants.
Competing interests: Authors declared no competing interests.

Study snapshot

Design	Narrative geroscience review
Model	Human and preclinical aging literature
Sample	Not applicable — review
Intervention	Not applicable; synthesis
Duration	Not applicable — review
Endpoints	Aging biology; Oxidative stress; Autophagy; Organ degeneration; Clinical translation

What the study showed, in plain terms

This 2026 review provides an up-to-date geroscience overview of spermidine across aging biology, age-related disease models and the path toward clinical translation.

Key findings

The modern mechanistic case remains strong, but the authors frame spermidine as a candidate for continued clinical testing rather than an established human geroprotective therapy.

What this study can and cannot tell us

Narrative review; it cannot substitute for large long-duration human outcome trials, which remain absent for lifespan and most age-related clinical endpoints.

Editorial review

Reviewed by the Biohack Blueprint research team

Khaled Mahmoud